A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

Slides:



Advertisements
Similar presentations
Cell Physiol Biochem 2013;32: DOI: /
Advertisements

Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. Effects of MAX reconstitution and of BRG1 depletion in lung cancer cells. A,
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia by Holly Edwards, Chengzhi Xie,
Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
Volume 71, Issue 6, Pages (June 2017)
MEL23 and MEL24 inhibit Mdm2 and p53 ubiquitination in cells.
NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.
Volume 15, Issue 1, Pages (January 2014)
Volume 14, Issue 12, Pages (March 2016)
DNAPKcs is required for DNA repair in the presence of androgen.
Stefan W. Stoll, Jessica L. Johnson, Yong Li, Laure Rittié, James T
Identification of TLOC1 and SKIL as tumor driver genes in 3q26.
Volume 23, Issue 1, Pages (January 2013)
Peroxisome Proliferator-Activated Receptor-α Is a Functional Target of p63 in Adult Human Keratinocytes  Silvia Pozzi, Michael Boergesen, Satrajit Sinha,
NF1 downregulation activates MAPK pathway signaling.
Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Volume 29, Issue 3, Pages (March 2016)
Yubao Wang, Ben B. Li, Jing Li, Thomas M. Roberts, Jean J. Zhao 
A, left: indicated MEFs were transfected as described in the Methods section. A, left: indicated MEFs were transfected as described in the Methods section.
Volume 23, Issue 3, Pages (March 2013)
Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.
Effect of small TbTim knockdown on cell growth.
Volume 12, Issue 4, Pages (October 2007)
Volume 20, Issue 2, Pages (July 2017)
Volume 24, Issue 2, Pages (July 2018)
Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.
Pharmacologically inhibiting BRAF/ERK and CDK4 restores APCFZR1 E3 ligase activity. Pharmacologically inhibiting BRAF/ERK and CDK4 restores APCFZR1 E3.
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 142, Issue 2, Pages (July 2010)
Volume 24, Issue 6, Pages (December 2016)
PERK signaling is constitutively activated upon EMT and promotes malignancy. PERK signaling is constitutively activated upon EMT and promotes malignancy.
Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.
Mechanism of piperlongumine induced Sp downregulation.
AML cells display differential sensitivity to inhibition of IKBKE and TBK1. AML cells display differential sensitivity to inhibition of IKBKE and TBK1.
eIF5A-PEAK1 signaling regulates KRAS protein expression.
Volume 8, Issue 5, Pages (September 2014)
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
TNFα is an important survival and growth signal for melanoma.
SiRNA screening identifies genes required for the viability of Pim1-ovexpressing prostate cells. siRNA screening identifies genes required for the viability.
The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.
Fig. 5 n-HA regulates gene expressions related to tumor suppression, calcium homeostasis, and immune response. n-HA regulates gene expressions related.
TGF-β1 modulates extracellular matrix–mediated MT1-MMP expression.
Sensor siRNAs can be used in high-order combinations.
Genome-wide Functional Analysis Reveals Factors Needed at the Transition Steps of Induced Reprogramming  Chao-Shun Yang, Kung-Yen Chang, Tariq M. Rana 
RNF2 promotes TGFβ signaling.
Cells lacking CDK6 kinase function are required to mutate p53.
Cell lines with aberrant expression of NRG1 are exquisitely sensitive to downregulation of ERBB3 signaling. Cell lines with aberrant expression of NRG1.
Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. Loss of HDAC3 inhibits CREBBP-mutant lymphoma growth in vitro and in vivo. A,
Tivantinib does not inhibit MET function.
BUB1B is validated as a candidate glioblastoma-lethal gene in vitro.
MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E. MAPK/ERK signaling regulates TLR4 gene expression in response to BRAFV600E.
Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Enhanced expression of Cap43 gene by nickel in breast cancer cell lines. Expression.
KRASG12D- and BRAFV600E-induced survival in PDECs requires IGF1R signaling. KRASG12D- and BRAFV600E-induced survival in PDECs requires IGF1R signaling.
Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer cell growth. Lapatinib cooperates with PLX4032 to inhibit BRAF-mutant thyroid cancer.
Interaction of NHEJ and HR pathways in PCO cultures.
P53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo CreER angiosarcoma. p53 restoration in a syngeneic transplant model of Mdm2Tg p53Neo/Neo.
Validation of MYC-driven drug responses.
G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. G34 H3K36me3 upregulates MYCN which is selectively.
In vivo shRNA screening in PDXs from 3 patients with melanoma.
LUBAC is essential for NF-κB activity in ABC DLBCL
H3K36me3 is not essential for LEDGF and MLL target gene occupancy.
I3C reduces the level of Cdc25A protein in breast cancer cells.
JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction. JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction.
AXL is not necessary for maintenance of intrinsic resistance.
Presentation transcript:

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A, outline of the pooled screening strategy used in-BRAFV600E A375 melanoma cells. A 90,000 shRNA-pooled lentiviral library targeting approximately 16,600 genes was introduced into the cells, and selection of infected cells was achieved using 0.5 μg/mL puromycin for 3 days. Cells were then treated with either DMSO or 3 μmol/L PLX4720 for up to 14 population doublings. shRNA sequences were amplified by PCR, and the relative abundance of each shRNA was determined by Illumina sequencing. PD, population doubling. B, growth of A375 cells infected with approximately 90,000 shRNAs and cultured in the presence of either DMSO or 3 μmol/L PLX4720 for up to 14 population doublings. C, the number of reads per shRNA was normalized and log2 transformed, and shRNA data for 2 DMSO controls and 6 PLX4720-treated replicas were analyzed using a “second-best shRNA”, 2-class comparison of log-fold change (LFC) in RIGER to generate a ranked list of genes that were enriched in the PLX4720-treated cells. The screening hits are visualized by plotting the function y = 1/normalized enrichment score (NES). The top 5-ranking candidate genes are indicated. D, heat map of shRNA representation across early time point (ETP), DMSO-, and PLX4720-treated replicas for the screen. shRNAs 39714 and 39717 were enriched across all drug-treated replicates. E, validation of shRNA-mediated knockdown of NF1 in A375 cells. A375 cells were infected with shRNAs against luciferase or NF1; after selection in puromycin, cell lysates were made and levels of NF1 protein were determined by Western blotting. F, A375 cells infected with either shLuc or shNF1 were cultured in the presence or absence of 3 μmol/L PLX4720 for 2 weeks. Cells were fixed, then stained with crystal violet and photographed. Steven R. Whittaker et al. Cancer Discovery 2013;3:350-362 ©2013 by American Association for Cancer Research